Drugs / VS-505
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04551300 | Oct 2020 → Jun 2022 | hyperphosphatemia | Shanghai Alebund Pharmaceuticals Limited | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VS-505 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04551300 ↗ |
| Known as | AP301 | “VS-505 (AP301), an acacia and ferric oxyhydroxide polymer” PMID 38453435 ↗ Sep 2024 |
| Modality | Other / unclassified | “an acacia and ferric oxyhydroxide polymer” PMID 38453435 ↗ Sep 2024 |
| Route | Oral | “oral VS-505 administered three times daily with meals” PMID 38453435 ↗ Sep 2024 |